Immune-mediated inflammatory diseases in patients with inflammatory bowel disease. Baseline data from the Aquiles study
Por:
Marin-Jimenez, I, Sanchez, VG, Gisbert, JP, Calle, JLP, Lujan, M, Abalos, JG, Tabernero, S, Julia, B, Romero, C, Cea-Calvo, L, Garcia-Vicuna, R, Vanaclocha, F
Publicada:
1 nov 2014
Resumen:
Objective: To determine the prevalence of immune-mediated inflammatory diseases (IMID) in a cohort of patients with inflammatory bowel disease (IBD) enrolled in hospital gastroenterology outpatients units for the AQUILES study, a prospective 2-year follow-up study.
Material and methods: We included patients >= 18 years old with a prior or new diagnosis of IBD (Crohn disease [CD], ulcerative colitis [UC] or indeterminate colitis). Diagnoses were collected in a cross-sectional manner from the clinical records at enrollment of a new patient in the study.
Results: We included 526 patients (mean age 40.2 years; 47.3% men, 52.7% women), 300 with CD (57.0%), 218 with UC (41.4%) and 8 with indeterminate colitis. Other types of IMID were present in 71 patients (prevalence: 13.5%, 95% CI: 10.8-16.7): 47 were spondyloarthropathies (prevalence: 8.9%); 18 psoriasis (3.4%); 5 pyoderma gangrenosum (1.0%), and 11 uveitis (2.1%). The prevalence of IMID was higher in patients with CD than in those with UC (17.0% [95% CI: 13.2-21.7] vs 9.2% [95% CI: 6.0-13.8], p = 0.011). In the multivariate analysis, the variables associated with the presence of IMID were diagnosis of CD (OR = 1.8 [95% CI: 1.1-3.2]) and duration of IBD >= 4 years (OR = 2.1 [95% CI: 1.1-4.1] in those with disease duration 4-8 years, and OR = 2.1 [95% CI: 1.2-3.9] in those with >= 8 years vs. <4 years).
Conclusions: In the cohort of patients with IBD in the AQUILES study, 13.5% had another IMID, with a higher prevalence in patients with CD and >4 years since disease onset. (C) 2013 Elsevier Espana, S.L.U. and AEEH y AEG. All rights reserved.
Filiaciones:
Marin-Jimenez, I:
Hosp Gregorio Maranon, Serv Gastroenterol, Madrid, Spain
Sanchez, VG:
Hosp Reina Sofia, Serv Gastroenterol, Cordoba, Spain
Gisbert, JP:
Hosp Univ La Princesa, Serv Gastroenterol, Inst Invest Sanitaria Princesa, Madrid, Spain
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Calle, JLP:
Hosp Univ Fdn Alcorcon, Serv Gastroenterol, Madrid, Spain
Lujan, M:
Consorcio Hosp Gen Univ Valencia, Serv Gastroenterol, Valencia, Spain
Abalos, JG:
Hosp Santa Creu & Sant Pau, Serv Gastroenterol, Barcelona, Spain
Tabernero, S:
Hosp Principe Asturias, Serv Gastroenterol, Madrid, Spain
Julia, B:
Merck Sharp & Dohme Espana, Dept Med, Madrid, Spain
Romero, C:
Merck Sharp & Dohme Espana, Dept Med, Madrid, Spain
Cea-Calvo, L:
Merck Sharp & Dohme Espana, Dept Med, Madrid, Spain
Garcia-Vicuna, R:
Hosp La Princesa, Serv Reumatol, Inst Invest Sanitaria Princesa, Madrid, Spain
Vanaclocha, F:
Hosp 12 Octubre, Serv Dermatol, E-28041 Madrid, Spain
|